DK2334703T3 - Sammensætninger og fremgangsmåder til påvisning af tlr3 - Google Patents

Sammensætninger og fremgangsmåder til påvisning af tlr3 Download PDF

Info

Publication number
DK2334703T3
DK2334703T3 DK09782995.6T DK09782995T DK2334703T3 DK 2334703 T3 DK2334703 T3 DK 2334703T3 DK 09782995 T DK09782995 T DK 09782995T DK 2334703 T3 DK2334703 T3 DK 2334703T3
Authority
DK
Denmark
Prior art keywords
antibody
tlr3
leu
antibodies
cells
Prior art date
Application number
DK09782995.6T
Other languages
English (en)
Inventor
Karine Chemin
Laurent Gauthier
Yannis Morel
Carine Paturel
Agnès Tisserant
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma filed Critical Innate Pharma
Application granted granted Critical
Publication of DK2334703T3 publication Critical patent/DK2334703T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Claims (13)

1. Monoklonalt antistof, der binder specifikt til et humant TLR3-polypeptid målt ved hjælp af genkendelse af paraffin-indlejrede 293T-celler, der er stabilt transficeret med TLR3, hvor antistoffet binder specifikt til TLR3-polypeptidet i paraffin-indlejrede cellepellets, og hvor antistoffet ikke binder til humant TLR4 i paraffin-indlejrede cellepellets.
2. Monoklonalt antistof ifølge krav 1, hvor antistoffet konkurrerer om binding til den samme TLR3-epitop som monoklonalt antistof 40F9 dannet af cellen, der er deponeret som 40F9.6 ved CNCM, Institut Pasteur, under nummer CNCM I-4061.
3. Monoklonalt antistof ifølge krav 1 til 2, hvor antistoffet omfatter en let kæde, der omfatter de tre CDR'er i 40F9-sekvensen for let kædes variable område ifølge SEQ ID NO: 3, og en tung kæde, der omfatter de tre CDR'er i 40F9-sekvensen for tung kædes variable område ifølge SEQ ID NO: 4.
4. Monoklonalt antistof ifølge krav 1 til 3, hvor antistoffet omfatter: (a) en tung kæde, der omfatter aminosyresekvensen ifølge SEQ ID NO: 3, der er fusioneret til et konstant område af en kappa-kæde; og (b) en let kæde, der omfatter aminosyresekvensen ifølge SEQ ID NO: 4, der er fusioneret til et konstant område af en IgG-kæde.
5. Antistof ifølge krav 1 til 4, hvor antistoffet er et antistoffragment, der er udvalgt blandt Fab, Fab', Fab'-SH, F(ab')2/ Fv, diabodies, enkeltkædet antistoffragment eller et multispecifikt antistof, der omfatter flere forskellige antistoffragmenter.
6. Antistof ifølge krav 1 til 5, hvor antistoffet er konjugeret eller kovalent bundet til en detekterbar del.
7. Antistof ifølge krav 1 til 6, hvor antistoffet binder specifikt til humane hud-, cerebellum-, bryst-, lunge-, oesophagus-, ventrikel-, ileum-, jejunum-, duodenum-, colon-, lever-, pankreas-, testis-, milt-, thymus-, thyreoidea- eller nyreceller.
8. Kit, der omfatter antistoffet ifølge et hvilket som helst af ovennævnte krav.
9. Kit ifølge krav 8, der yderligere omfatter et mærket sekundært antistof, der specifikt genkender antistoffet ifølge et hvilket som helst af ovennævnte krav.
10. Kit ifølge krav 9, hvor det sekundære antistof er konjugeret til HRP eller AP.
11. Hybridom eller rekombinant værtscelle, der danner antistoffet ifølge krav 1 til 7.
12. In vi tro-fremgangsmåde til detektion af et TLR3-polypeptid, hvilken fremgangsmåde omfatter tilvejebringelse af et paraffin-indlejret vævssnit fra en patient og detektion af TLR3-niveauet i vævssnittet ved anvendelse af et monoklonalt antistof ifølge krav 1 til 7, der binder specifikt til TLR3-polypeptidet i paraffin-indlejrede vævssnit.
13. Monoklonalt antistof ifølge krav 1 til anvendelse som et diagnostisk middel.
DK09782995.6T 2008-09-17 2009-09-15 Sammensætninger og fremgangsmåder til påvisning af tlr3 DK2334703T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9767608P 2008-09-17 2008-09-17
PCT/EP2009/061902 WO2010031749A1 (en) 2008-09-17 2009-09-15 Compositions and methods for detecting tlr3

Publications (1)

Publication Number Publication Date
DK2334703T3 true DK2334703T3 (da) 2015-10-05

Family

ID=41459807

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09782995.6T DK2334703T3 (da) 2008-09-17 2009-09-15 Sammensætninger og fremgangsmåder til påvisning af tlr3

Country Status (4)

Country Link
US (3) US8273541B2 (da)
EP (1) EP2334703B1 (da)
DK (1) DK2334703T3 (da)
WO (1) WO2010031749A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8460659B2 (en) 2008-10-31 2013-06-11 Janssen Biotech, Inc. Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases
PE20110808A1 (es) 2008-10-31 2011-10-31 Janssen Biotech Inc Anticuerpos contra el receptor 3 de tipo toll
ES2930651T3 (es) * 2011-09-06 2022-12-20 Becton Dickinson Co Métodos y composiciones para la detección citométrica de células tumorales circulantes en una muestra
US10105305B2 (en) * 2014-02-19 2018-10-23 The Johns Hopkins University Compositions and methods for promoting skin regeneration and hair growth
CN106414726A (zh) 2014-04-07 2017-02-15 米纳瓦生物技术公司 抗nme抗体
EP3774924A1 (en) * 2018-04-09 2021-02-17 Mor Research Applications Ltd. Anti-telomerase reverse transcriptase antibodies and use thereof
EP3920693A4 (en) 2019-02-04 2022-10-05 Minerva Biotechnologies Corporation ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS
WO2020232226A1 (en) 2019-05-16 2020-11-19 The Johns Hopkins University Compositions and methods for skin rejuvenation
CN116367857A (zh) 2020-06-08 2023-06-30 米纳瓦生物技术公司 抗nme抗体及治疗癌症或癌症转移的方法
KR20230028796A (ko) * 2020-06-26 2023-03-02 미네르바 바이오테크놀로지 코포레이션 항-nme 항체 및 암 또는 암 전이의 치료 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
DK130991D0 (da) 1991-07-04 1991-07-04 Immunodex K S Polymere konjugater
EP0594772B1 (en) 1991-07-04 1996-08-28 Immunodex K/S Water-soluble, polymer-based reagents and conjugates comprising moieties derived from divinyl sulfone
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
ATE458053T1 (de) 1997-05-07 2010-03-15 Schering Corp Menschliche toll-like-rezeptorproteine, zugehörige reagenzien und verfahren
CA2587676A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
EP1833996B1 (en) 2005-01-06 2012-12-05 Genentech, Inc. Cancer prognostic methods

Also Published As

Publication number Publication date
US20120308581A1 (en) 2012-12-06
EP2334703A1 (en) 2011-06-22
US8715667B2 (en) 2014-05-06
EP2334703B1 (en) 2015-07-08
WO2010031749A9 (en) 2010-05-14
US20110212110A1 (en) 2011-09-01
US20140234323A1 (en) 2014-08-21
US8273541B2 (en) 2012-09-25
WO2010031749A1 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
DK2334703T3 (da) Sammensætninger og fremgangsmåder til påvisning af tlr3
JP7479435B2 (ja) 癌治療および判断ターゲットとしてのｌｙ７５
JP6636016B2 (ja) 抗ｂ７−ｈ３抗体及びその診断用途
CN105143266B (zh) 包含dll3结合试剂的癌症的治疗和诊断靶标
JP2017518366A (ja) Ｐｄ−ｌ１抗体及びその使用
JP2017532025A (ja) 交差反応性ｓｉｇｌｅｃ抗体
JP6944925B2 (ja) 組織浸潤ｎｋ細胞を検出する方法
KR20140048303A (ko) 암의 검출 및 진단을 위한 새로운 항-cxcr4 항체 및 그의 용도
US20210009683A1 (en) Anti-aggrus monoclonal antibody, domain in aggrus which is required for binding to clec-2, and method for screening for aggrus-clec-2 binding inhibitor
CN107430125A (zh) 通过抑制tmcc3以抑制癌症的方法
JP6113721B2 (ja) 治療標的及び診断標的
EP2738250B1 (en) Anti-beta1,6-N-acetylglucosaminyltransferase 5B antibody for detecting epithelial ovarian cancer and method for diagnosing epithelial ovarian cancer
JP2024513880A (ja) 免疫組織化学法およびｋｉｒ３ｄｌ２特異的薬剤
KR20170138465A (ko) Igf-1r 항체 및 암의 진단을 위한 그의 용도
JP7821779B2 (ja) 抗体を使用した細胞表面ｍｉｃａ及びｍｉｃｂの検出
US20060029987A1 (en) Diagnosis of pancreatic cancer by using pancreatic targets